Business
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"text","content":"The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston.Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular cure as determined by an FDA-approved nucleic acid test (NAT).Study is the world’s first and only clinical trial evaluating tafenoquine in human babesiosis patients. WASHINGTON, June 27, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that the first patient has been enrolled in a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. The patient was enrolled at Tufts Medical Center in Boston. The study will enroll at least 24, and as many as 33 people. It is the world's first and only clinical trial evaluating the efficacy and safety of tafenoquine in human patients who have been diagnosed with acute babesiosis. \"With the first patient now enrolled in this groundbreaking clinical study, we have moved into a key phase of development with tafenoquine as a potential new treatment option in treating babesiosis,” said Geoff Dow, PhD, chief executive officer at 60 Degrees Pharmaceuticals. “Given both the growing prevalence of babesiosis and the difficulty of quickly differentiating it from other illnesses seen in the clinic, we anticipate the numbers of people hospitalized with this serious tick-borne illness will continue to rise over time. In such cases, babesiosis can certainly become life-threatening. Our goal is for tafenoquine to play an important role in safely and effectively resolving babesiosis in those patients.” Babesiosis is a steadily emerging, tick-borne disease transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease. An orphan disease, babesiosis may be life-threatening in elderly and immunosuppressed patients. The Company is in discussions with other prominent university hospitals to participate in the tafenoquine for babesiosis study. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA®. The s...